The Effect of Adding Pertuzumab to Adjuvant Trastuzumab in Early HER2-Positive Breast Cancer
DOI:
https://doi.org/10.22317/jcms.v9i3.1351Keywords:
Breast Neoplasms, HER2-positive, Drug TherapyAbstract
Objectives: In this trial, It has been investigated whether pertuzumab, when added to adjuvant trastuzumab and chemotherapy, improves outcomes among patients with HER2-positive early breast cancer in compares to patients who received only Herceptin
Methods: After surgery and central HER2-positive confirmation, about randomly 220 patients assigned with high-risk HER2-positive, operable breast cancer to received Anthracycline based chemotherapy 3 cycles fallowed by Taxotere 3 + either pertuzumab + hercetin 3 or standard adjuvant Herceptin alone, 17 cycles in 1 year. The patients were followed up for 3 years.
Results: Results were indicated that about 50% of the patients who were randomly assigned to arm A received pertuzumab+Herceptin 3 cycles every 3 weeks (110 patients) and arm B 50% (110 patients) received Herceptin alone 17 cycles every 3 weeks. Disease recurrence occurred in 12 patients (10.9 %) in the pertuzumab group and 8 patients (7.2%) in the arm B group (hazard ratio, 0.81; 95% confidence interval [CI], 0.66 to 1.00; P=0.045). The estimates of the 3-year rates of invasive-disease-free survival were 89% in the pertuzumab+ herceptin group and 93% in the herceptin group. Heart failure, cardiac death, and cardiac dysfunction were infrequent in both treatment groups. Diarrhea of grade 3 or higher occurred almost exclusively during chemotherapy and it was more frequent with pertuzumab than with group B (7.9% vs. 2.8%).
Conclusions: The study showed that pertuzumab + Trastuzumab adjuvant in 3 cycles worse rates of invasive-disease-free survival among patients with HER2-positive, operable breast cancer in compares with classical trastuzumab alone in 17 cycles. Diarrhea was more common with pertuzumab than with classical Trastuzumab therapy.
References
Zambelli, A., Pappagallo, G. and Marchetti, P., 2020. Adding pertuzumab to adjuvant therapy for high-risk HER2-positive early breast cancer in APHINITY: a GRADE analysis. Journal of Comparative Effectiveness Research, 9(6), pp.423-430.
Miller KD. Questioning our APHINITY for More. N. Engl. J. Med. 377(2), 186–187 (2017).
Von Minckwitz G, Huang CS, Mano MS et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med. 380(7), 617–628 (2019).
Martin M, Holmes FA, Ejlertsen B et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, Phase III trial. Lancet Oncol. 18(12), 1688–1700 (2017)
Romond E.H., Perez E.A., Bryant J., et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353:1673–84.
Zardavas D., Fouad T.M., Piccart M. (2015). Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015. Breast, 24(Suppl 2):S143–S148.
Baselga J., Swain S.M. (2009). Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer, 9:463–75.
Swain S.M., Baselga J., Kim S.B., et al. (2015). Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med., 372:724–34
Swain S.M., Ewer MS., Cortés J., et al. (2013). Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist., 18:257–64
Baselga J., Cortés J., Kim S.B., et al. (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med., 366:109–19.
Gianni L., Pienkowski T., Im Y.H., et al. (2016). 5-Year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (Neo-Sphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol., 17:791–800.
Wolff A.C., Hammond M.E.H., Hicks DG, et al. (2013). Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol., 31:3997–4013.
Connolly R.M., Leal J.P., Solnes L., et al. (2019). TBCRC026: phase II trial correlating standardized uptake value with pathologic complete response to pertuzumab and trastuzumab in breast cancer. J Clin Oncol., 37(9):714–722.
Kurzeder C., Bover I., Marme F., et al. (2016). Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-expressing platinum-resistant ovarian cancer (PENELOPE). J Clin Oncol., 34(21):2516–2525.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
